217 related articles for article (PubMed ID: 24616378)
1. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.
Järås M; Miller PG; Chu LP; Puram RV; Fink EC; Schneider RK; Al-Shahrour F; Peña P; Breyfogle LJ; Hartwell KA; McConkey ME; Cowley GS; Root DE; Kharas MG; Mullally A; Ebert BL
J Exp Med; 2014 Apr; 211(4):605-12. PubMed ID: 24616378
[TBL] [Abstract][Full Text] [Related]
2. Casein kinase 1α inhibits p53 downstream of MDM2‑mediated autophagy and apoptosis in acute myeloid leukemia.
Xu W; Huang Z; Gan Y; Chen R; Huang Y; Xue B; Jiang S; Yu Z; Yu K; Zhang S
Oncol Rep; 2020 Nov; 44(5):1895-1904. PubMed ID: 32901886
[TBL] [Abstract][Full Text] [Related]
3. Csnk1a1 inhibition modulates the inflammatory secretome and enhances response to radiotherapy in glioma.
Liu G; Li H; Zhang W; Yu J; Zhang X; Wu R; Niu M; Liu X; Yu R
J Cell Mol Med; 2021 Aug; 25(15):7395-7406. PubMed ID: 34216174
[TBL] [Abstract][Full Text] [Related]
4. Targeting Csnk1a1 in leukemia.
Stegmaier K
J Exp Med; 2014 Apr; 211(4):594. PubMed ID: 24711612
[No Abstract] [Full Text] [Related]
5. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.
Minzel W; Venkatachalam A; Fink A; Hung E; Brachya G; Burstain I; Shaham M; Rivlin A; Omer I; Zinger A; Elias S; Winter E; Erdman PE; Sullivan RW; Fung L; Mercurio F; Li D; Vacca J; Kaushansky N; Shlush L; Oren M; Levine R; Pikarsky E; Snir-Alkalay I; Ben-Neriah Y
Cell; 2018 Sep; 175(1):171-185.e25. PubMed ID: 30146162
[TBL] [Abstract][Full Text] [Related]
6. Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.
Fuchs SNR; Stalmann USA; Snoeren IAM; Bindels E; Schmitz S; Banjanin B; Hoogenboezem RM; van Herk S; Saad M; Walter W; Haferlach T; Seillier L; Saez-Rodriguez J; Dugourd AJF; Lehmann KV; Ben-Neriah Y; Gleitz HFE; Schneider RK
Blood Adv; 2024 Feb; 8(3):766-779. PubMed ID: 38147624
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of Csnk1a1 results in preimplantation developmental arrest in mice.
Ma Z; Zheng H; Li X; Yu B; Peng H
Theriogenology; 2023 Mar; 198():30-35. PubMed ID: 36542875
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
[TBL] [Abstract][Full Text] [Related]
9. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
Dos Santos C; McDonald T; Ho YW; Liu H; Lin A; Forman SJ; Kuo YH; Bhatia R
Blood; 2013 Sep; 122(11):1900-13. PubMed ID: 23896410
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
[TBL] [Abstract][Full Text] [Related]
11. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
12. CKIα ablation highlights a critical role for p53 in invasiveness control.
Elyada E; Pribluda A; Goldstein RE; Morgenstern Y; Brachya G; Cojocaru G; Snir-Alkalay I; Burstain I; Haffner-Krausz R; Jung S; Wiener Z; Alitalo K; Oren M; Pikarsky E; Ben-Neriah Y
Nature; 2011 Feb; 470(7334):409-13. PubMed ID: 21331045
[TBL] [Abstract][Full Text] [Related]
13. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
14. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
15. HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
Qi J; Singh S; Hua WK; Cai Q; Chao SW; Li L; Liu H; Ho Y; McDonald T; Lin A; Marcucci G; Bhatia R; Huang WJ; Chang CI; Kuo YH
Cell Stem Cell; 2015 Nov; 17(5):597-610. PubMed ID: 26387755
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
17. CSNK1a1 Regulates PRMT1 to Maintain the Progenitor State in Self-Renewing Somatic Tissue.
Bao X; Siprashvili Z; Zarnegar BJ; Shenoy RM; Rios EJ; Nady N; Qu K; Mah A; Webster DE; Rubin AJ; Wozniak GG; Tao S; Wysocka J; Khavari PA
Dev Cell; 2017 Oct; 43(2):227-239.e5. PubMed ID: 28943242
[TBL] [Abstract][Full Text] [Related]
18. Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells.
Park SM; Miyamoto DK; Han GYQ; Chan M; Curnutt NM; Tran NL; Velleca A; Kim JH; Schurer A; Chang K; Xu W; Kharas MG; Woo CM
Cancer Cell; 2023 Apr; 41(4):726-739.e11. PubMed ID: 36898380
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitination of UVRAG by SMURF1 promotes autophagosome maturation and inhibits hepatocellular carcinoma growth.
Feng X; Jia Y; Zhang Y; Ma F; Zhu Y; Hong X; Zhou Q; He R; Zhang H; Jin J; Piao D; Huang H; Li Q; Qiu X; Zhang Z
Autophagy; 2019 Jul; 15(7):1130-1149. PubMed ID: 30686098
[TBL] [Abstract][Full Text] [Related]
20. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
